摘要
目的:观察痰热清联合沐舒坦治疗急性加重期慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)的临床疗效,并分析滴注时间与疗效的相关性。方法:60例急性加重期COPD患者为研究对象,随机分为治疗Ⅰ组、治疗Ⅱ组、治疗Ⅲ组,分别治疗8 d、12 d、16 d。比较3组患者的临床疗效和相关指标。结果:治疗Ⅱ组、治疗Ⅲ组临床疗效、Pa O2和Pa CO2改善情况优于治疗Ⅰ组,差异有统计学意义(P<0.05)。3组患者痰液中白细胞介素-8(interleukin-8,IL-8)、肿瘤坏死因子-α(tumor necrosis factor,TNF-α)和脂质过氧化物(lipid peroxide,LPO)水平均下降,而超氧化物歧化酶(superoxide dismutase,SOD)水平有所升高,差异均有统计学意义(P<0.05);治疗Ⅱ组、治疗Ⅲ组显著优于治疗Ⅰ组(P<0.05);治疗Ⅲ组显著优于治疗Ⅱ组(P<0.05)。结论:痰热清联合沐舒坦治疗急性加重期COPD疗效较好,二者滴注时间对急性加重期COPD患者的应用价值更大。
Objective：To observe the curative effects on the treatment of acute exacerbation chronic obstructive pulmonary disease by Tanreqing combined with mucosolvan and analyzing the correlation of instilling time and curative effect. Methods ：60 cases were random- ly divided into treatment group Ⅰ , treatment group Ⅱ , treatment group Ⅲ, respectively treating 8 d, 12 d, 16 d, Comparing the clinical effects and index of correlation. Results ： In the treatment group Ⅱ and treatment group Ⅲ, the curative effects and improving of PaO2 and PaCO2 are superior to the group Ⅰ. The difference was statistically significant （P 〈 0.05）. The patients of three groups with sputum IL-8,TNF-a and LPO level decreased, but SOD level was increased, the differences were statistically significant （ P 〈 0.05 ）. Group Ⅲ and Ⅱare superior to group Ⅰ （P 〈0.05） ;group Ⅲ is superior to the group Ⅱ（P 〈0.05）. Conclusion：It＇s good for the acute exacerba- tion chronic obstructive pulmonary disease by Tanreqing combined with mucosolvan.
出处
《中医学报》
CAS
2015年第8期1109-1110,共2页
Acta Chinese Medicine
基金
四川省教育厅课题项目(14ZB0021)
关键词
慢性阻塞性肺疾病
痰热清
沐舒坦
chronic obstructive pulmonary disease
tanreqing
mucosolvan
